<DOC>
	<DOCNO>NCT02173795</DOCNO>
	<brief_summary>The primary objective study investigate patient acceptability / preference Berodual® Respimat® inhaler compare conventional Berodual® Metered Aerosol ( MA ) inhaler . Ease handle assemble Respimat® inhaler home real life condition also evaluate .</brief_summary>
	<brief_title>Berodual® Respimat® Versus Berodual® Metered Aerosol ( MA ) Inhaler Patients With Asthma , Chronic Obstructive Pulmonary Disease , Mixed Condition</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Diagnosis chronic obstructive pulmonary disease , asthma , mixed condition minimum 6 month Male female patient 18 year age old Patients use least 2 puff t.i.d . Berodual® MA HFA regular use least 4 week prior study Patients able perform study related test include use peak flow meter , perform acceptable PEFR measurement , able maintain record ( Patient Daily Diary Cards ) study period require protocol All patient must sign Informed Consent Form prior participation trial , i.e. , prior runin period accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Patients significant disease chronic airway obstruction ( CAO ) exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients recent history ( i.e. , six month less ) myocardial infarction Patients cardiac arrhythmia require drug therapy hospitalize heart failure within past three year , include patient hypertrophic cardiomyopathy tachyarrhythmia Patients regularly use oxygen therapy Patients know active tuberculosis Patients history cancer within last five year . Patients treat basal cell carcinoma allow Patients history lifethreatening pulmonary obstruction , history cystic fibrosis clinically evident bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 Patients upper low respiratory infection past six week prior screen visit ( Visit 1 ) runin period Patients hospitalize visit emergency room past six week runin period Patients currently pulmonary rehabilitation programme maintain throughout duration study complete pulmonary rehabilitation programme six week prior screen visit ( Visit 1 ) Patients know hypersensitivity anticholinergic drug component trial medication include excipients Patients medically treat prostatic hyperplasia bladder neck obstruction Patients know narrowangle glaucoma raise intraocular pressure Patients treat betablocker medication Note : beta1blocker eye medication treatment nonnarrow angle glaucoma allow Patients use oral corticosteroid medication unstable dose ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisolone per day 20 mg every day Patients inhale shortacting betaadrenergics study medication Patients inhale shortacting betaanticholinergics study medication Patients take monoamine oxidase inhibitor Patients take tricyclic antidepressant Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous three month ( i.e. , oral contraceptive , intrauterine inhaler , diaphragm subdermal implant ) Patients history and/or active significant alcohol drug abuse Patients take investigational drug within one month six halflives ( whichever great ) prior screen visit ( Visit 1 ) Patients already enrol randomised treatment group study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>